Genefit (GNFTF) 27.3000 $GNFTF GENFIT to Begin
Post# of 273249
Posted On: 08/17/2016 9:13:48 AM
Genefit (GNFTF) 27.3000 $GNFTF
GENFIT to Begin Elafibranor Clinical Program in PBC
BusinessWire - Thu Mar 31, 8:27AM CDT
--Elafibranor in pediatric NASH
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 172.16 (-2.42), LLY: 79.84 (-0.42), GSK: 44.45 (+0.13), AGN: 253.19 (-0.86), ABUS: 3.75 (-0.06), ACST: 1.42 (unch), ISIS: 57.56 (-0.28), AZN: 33.52 (-0.03), CBAY: 2.30 (+0.09)
Global Non-Alcoholic SteatoHepatitis (NASH) Analysis 2015 - Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunities
M2 - Fri Dec 11, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/m95wfc/nonalcoholic) has announced the addition of the "Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies" report to their offering. Sales of Hepatitis C drugs crossed -$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities. As per the US Association of Liver Disease, of those who develop NASH, -15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over -$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life. Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of -$450-600mn. This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH. Key Topics Covered: 1. Executive Summary 2. Overview of NASH 2.1 Possible targets for the treatment of NASH 2.2 Drugs in the pipeline 2.3 Key Milestones 2.4 Drivers of M&A/ Licensing deals in NASH 2.5 NASH disease market opportunity to 2025 3. Products in Development and Competitive Landscape 3.1 Key Drugs/Companies Developing Drugs Against NASH 3.1.1 Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo 3.1.2 Elafibranor - Genfit 3.1.3 Multiple programs - Gilead 3.1.4 Emricasan - Conatus Pharmaceuticals 3.1.5 Aramchol - Galmed Pharmaceuticals 3.1.6 Cenicriviroc - Tobira Therapeutics 3.1.7 IMM-124E - Immuron 3.1.8 GR-MD-02 - Galectin Therapeutics 3.1.9 TD139 - Galecto Biotech 3.1.10 SHP626 - Shire 3.1.11 PXS4728A - Boehringer Ingelheim 3.2 Repurposed Drugs for NASH 3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma 3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare 3.2.3 Victoza (liraglutide) - Novo Nordisk 4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment 4.1 Cause, Symptoms, Pathogenesis, Diagnosis 4.2 Current treatment including Herbal Medicine 5. Regulatory Pathway 5.1 Challenges in trials using endpoints to define clinically meaningful benefits 5.2 Potential Clinical Trial Design for NASH and Endpoints 6. Annexure Companies Mentioned - Boehringer Ingelheim - Cadila Healthcare - Conatus Pharmaceuticals - Galectin Therapeutics - Galecto Biotech - Galmed Pharmaceuticals - Genfit - Gilead - Immuron, - Intercept Pharmaceuticals/ Dainippon Sumitomo - Islet Sciences/BHV pharma - Novo Nordisk - Shire - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/m9...nalcoholic
NVO: 46.63 (-0.49), GLMD: 4.14 (+0.11), GILD: 79.40 (+0.15), MRK: 63.04 (-0.28), CNAT: 1.95 (-0.03), GALT: 1.88 (-0.03), ICPT: 164.15 (-0.90), TBRA: 4.79 (-0.28)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 15.94 (-0.06), ZFGN: 3.26 (-0.07), AQXP: 9.32 (-0.37), GALT: 1.88 (-0.03), RGLS: 3.46 (-0.18), BMY: 59.55 (+0.14), DRRX: 1.96 (+0.05), ENTA: 23.15 (-0.45), NVO: 46.63 (-0.49), GILD: 79.40 (+0.15), SHPG: 197.47 (-1.86), MRK: 63.04 (-0.28), VBAY: (), VBLT: 4.10 (+0.04), VKTX: 1.27 (unch), NVS: 81.86 (+0.09)
Nonalcoholic Steatohepatitis (NASH) Commercial Opportunities - Pipeline Analysis & Forecast Report
M2 - Mon Dec 07, 8:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/p3853f/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. NASH Facts: - 10% of the adult population in U.S has NASH - NASH can occur in all age groups and even in children but mostly it is diagnosed in the patients between the age of 40-60 - NASH affects between 9.5-16 million people in United States accounting for 3 to 5 % of the population - NASH is a third leading and rapidly increasing indication for liver transplants accounting for 10% of liver transplants in U.S. - In America, the obesity rate has doubled in adults and tripled in children in the past 10 years which would impact the prevalence of NASH in the coming years, being one of the major risk factors for NASH - NASH has the potential to become one of the leading cause of end stage liver disease, liver transplantation, and hepatocellular carcinoma in the next decades This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Companies Mentioned: - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics Report Structure: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players 15. References For more information visit http://www.researchandmarkets.com/research/p3...nalcoholic
GILD: 79.40 (+0.15), VKTX: 1.27 (unch)
GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input
BusinessWire - Mon Nov 16, 2:29AM CST
--Additional GOLDEN 505 trial data presented at AASLD further demonstrate efficacy, cardiometabolic benefit, safety and good tolerability of Elafibranor
Global Insulin Resistance Pipeline Review 2015 - 9 Companies & 19 Drug Profiles
M2 - Tue Sep 08, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z47c8s/insulin) has announced the addition of the "Insulin Resistance - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AUS Bio Limited - Genfit SA - GlaxoSmithKline Plc - Hadasit Medical Research Services & Development Ltd - Mertiva AB - Mochida Pharmaceutical Co., Ltd. - Novartis AG - Prometheon Pharma, LLC - Sanofi Drug Profiles - 6860766 - BVS-857 - Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - elafibranor - englerin A - MD-960 - Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - PEG-Catalase - Peptide for Obesity and Insulin Resistance - SAR-088 - SERX-1 - Small Molecule for Hypertension and Insulin Resistance - Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance For more information visit http://www.researchandmarkets.com/research/z47c8s/insulin
GSK: 44.45 (+0.13), NVS: 81.86 (+0.09)
Non-Alcoholic Steatohepatitis Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks9fl3/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" report to their offering. Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015 provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Genextra S.p.a. - Genfit SA - Cempra, Inc. - Raptor Pharmaceuticals Corp. - Nimbus Therapeutics, LLC - Immuron Limited - Gilead Sciences, Inc. - Galmed International Ltd. - Galectin Therapeutics, Inc. - DURECT Corporation Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - University of California, San Diego - National Nutrition and Food Technology Research Institute - Yokohama City University - Bambino Gesu Hospital and Research Institute - Ghent University Hospital - Gunma Liver Study Group - Hadassah Medical Organization - Hiroshima University Hospital For more information visit http://www.researchandmarkets.com/research/ks...nalcoholic
RPTP: 6.53 (-0.26), GILD: 79.40 (+0.15), GALT: 1.88 (-0.03), DRRX: 1.96 (+0.05), CEMP: 23.50 (+0.52)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 79.40 (+0.15), VKTX: 1.27 (unch)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 79.40 (+0.15), GALT: 1.88 (-0.03), FGEN: 18.39 (-0.86), VBAY: (), VBLT: 4.10 (+0.04), CELGZ: 1.11 (-0.12)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 79.40 (+0.15), PFE: 34.79 (unch), GALT: 1.88 (-0.03), FGEN: 18.39 (-0.86), CELGZ: 1.11 (-0.12)
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Apr 13, 4:18AM CDT
Summary
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 120.30 (-0.03), GTXI: 0.57 (+0.02), ESPR: 10.79 (-0.20), ISIS: 57.56 (-0.28), PFE: 34.79 (unch), NEOT: 0.89 (-0.03), AMGN: 172.16 (-2.42), LLY: 79.84 (-0.42), GSK: 44.45 (+0.13)
GENFIT to Begin Elafibranor Clinical Program in PBC
BusinessWire - Thu Mar 31, 8:27AM CDT
--Elafibranor in pediatric NASH
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 172.16 (-2.42), LLY: 79.84 (-0.42), GSK: 44.45 (+0.13), AGN: 253.19 (-0.86), ABUS: 3.75 (-0.06), ACST: 1.42 (unch), ISIS: 57.56 (-0.28), AZN: 33.52 (-0.03), CBAY: 2.30 (+0.09)
Global Non-Alcoholic SteatoHepatitis (NASH) Analysis 2015 - Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunities
M2 - Fri Dec 11, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/m95wfc/nonalcoholic) has announced the addition of the "Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies" report to their offering. Sales of Hepatitis C drugs crossed -$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities. As per the US Association of Liver Disease, of those who develop NASH, -15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over -$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life. Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of -$450-600mn. This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH. Key Topics Covered: 1. Executive Summary 2. Overview of NASH 2.1 Possible targets for the treatment of NASH 2.2 Drugs in the pipeline 2.3 Key Milestones 2.4 Drivers of M&A/ Licensing deals in NASH 2.5 NASH disease market opportunity to 2025 3. Products in Development and Competitive Landscape 3.1 Key Drugs/Companies Developing Drugs Against NASH 3.1.1 Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo 3.1.2 Elafibranor - Genfit 3.1.3 Multiple programs - Gilead 3.1.4 Emricasan - Conatus Pharmaceuticals 3.1.5 Aramchol - Galmed Pharmaceuticals 3.1.6 Cenicriviroc - Tobira Therapeutics 3.1.7 IMM-124E - Immuron 3.1.8 GR-MD-02 - Galectin Therapeutics 3.1.9 TD139 - Galecto Biotech 3.1.10 SHP626 - Shire 3.1.11 PXS4728A - Boehringer Ingelheim 3.2 Repurposed Drugs for NASH 3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma 3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare 3.2.3 Victoza (liraglutide) - Novo Nordisk 4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment 4.1 Cause, Symptoms, Pathogenesis, Diagnosis 4.2 Current treatment including Herbal Medicine 5. Regulatory Pathway 5.1 Challenges in trials using endpoints to define clinically meaningful benefits 5.2 Potential Clinical Trial Design for NASH and Endpoints 6. Annexure Companies Mentioned - Boehringer Ingelheim - Cadila Healthcare - Conatus Pharmaceuticals - Galectin Therapeutics - Galecto Biotech - Galmed Pharmaceuticals - Genfit - Gilead - Immuron, - Intercept Pharmaceuticals/ Dainippon Sumitomo - Islet Sciences/BHV pharma - Novo Nordisk - Shire - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/m9...nalcoholic
NVO: 46.63 (-0.49), GLMD: 4.14 (+0.11), GILD: 79.40 (+0.15), MRK: 63.04 (-0.28), CNAT: 1.95 (-0.03), GALT: 1.88 (-0.03), ICPT: 164.15 (-0.90), TBRA: 4.79 (-0.28)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 15.94 (-0.06), ZFGN: 3.26 (-0.07), AQXP: 9.32 (-0.37), GALT: 1.88 (-0.03), RGLS: 3.46 (-0.18), BMY: 59.55 (+0.14), DRRX: 1.96 (+0.05), ENTA: 23.15 (-0.45), NVO: 46.63 (-0.49), GILD: 79.40 (+0.15), SHPG: 197.47 (-1.86), MRK: 63.04 (-0.28), VBAY: (), VBLT: 4.10 (+0.04), VKTX: 1.27 (unch), NVS: 81.86 (+0.09)
Nonalcoholic Steatohepatitis (NASH) Commercial Opportunities - Pipeline Analysis & Forecast Report
M2 - Mon Dec 07, 8:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/p3853f/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. NASH Facts: - 10% of the adult population in U.S has NASH - NASH can occur in all age groups and even in children but mostly it is diagnosed in the patients between the age of 40-60 - NASH affects between 9.5-16 million people in United States accounting for 3 to 5 % of the population - NASH is a third leading and rapidly increasing indication for liver transplants accounting for 10% of liver transplants in U.S. - In America, the obesity rate has doubled in adults and tripled in children in the past 10 years which would impact the prevalence of NASH in the coming years, being one of the major risk factors for NASH - NASH has the potential to become one of the leading cause of end stage liver disease, liver transplantation, and hepatocellular carcinoma in the next decades This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Companies Mentioned: - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics Report Structure: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players 15. References For more information visit http://www.researchandmarkets.com/research/p3...nalcoholic
GILD: 79.40 (+0.15), VKTX: 1.27 (unch)
GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input
BusinessWire - Mon Nov 16, 2:29AM CST
--Additional GOLDEN 505 trial data presented at AASLD further demonstrate efficacy, cardiometabolic benefit, safety and good tolerability of Elafibranor
Global Insulin Resistance Pipeline Review 2015 - 9 Companies & 19 Drug Profiles
M2 - Tue Sep 08, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z47c8s/insulin) has announced the addition of the "Insulin Resistance - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AUS Bio Limited - Genfit SA - GlaxoSmithKline Plc - Hadasit Medical Research Services & Development Ltd - Mertiva AB - Mochida Pharmaceutical Co., Ltd. - Novartis AG - Prometheon Pharma, LLC - Sanofi Drug Profiles - 6860766 - BVS-857 - Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - elafibranor - englerin A - MD-960 - Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - PEG-Catalase - Peptide for Obesity and Insulin Resistance - SAR-088 - SERX-1 - Small Molecule for Hypertension and Insulin Resistance - Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance For more information visit http://www.researchandmarkets.com/research/z47c8s/insulin
GSK: 44.45 (+0.13), NVS: 81.86 (+0.09)
Non-Alcoholic Steatohepatitis Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks9fl3/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" report to their offering. Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015 provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Genextra S.p.a. - Genfit SA - Cempra, Inc. - Raptor Pharmaceuticals Corp. - Nimbus Therapeutics, LLC - Immuron Limited - Gilead Sciences, Inc. - Galmed International Ltd. - Galectin Therapeutics, Inc. - DURECT Corporation Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - University of California, San Diego - National Nutrition and Food Technology Research Institute - Yokohama City University - Bambino Gesu Hospital and Research Institute - Ghent University Hospital - Gunma Liver Study Group - Hadassah Medical Organization - Hiroshima University Hospital For more information visit http://www.researchandmarkets.com/research/ks...nalcoholic
RPTP: 6.53 (-0.26), GILD: 79.40 (+0.15), GALT: 1.88 (-0.03), DRRX: 1.96 (+0.05), CEMP: 23.50 (+0.52)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 79.40 (+0.15), VKTX: 1.27 (unch)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 79.40 (+0.15), GALT: 1.88 (-0.03), FGEN: 18.39 (-0.86), VBAY: (), VBLT: 4.10 (+0.04), CELGZ: 1.11 (-0.12)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 79.40 (+0.15), PFE: 34.79 (unch), GALT: 1.88 (-0.03), FGEN: 18.39 (-0.86), CELGZ: 1.11 (-0.12)
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Apr 13, 4:18AM CDT
Summary
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 120.30 (-0.03), GTXI: 0.57 (+0.02), ESPR: 10.79 (-0.20), ISIS: 57.56 (-0.28), PFE: 34.79 (unch), NEOT: 0.89 (-0.03), AMGN: 172.16 (-2.42), LLY: 79.84 (-0.42), GSK: 44.45 (+0.13)
(0)
(0)Scroll down for more posts ▼